DTC.CN - Defence Therapeutics Inc.
| Previous Close | 2.7000 |
| Open | 2.6000 |
| Bid | 2.6000 x N/A |
| Ask | 2.6100 x N/A |
| Day's Range | 2.6000 - 2.6100 |
| 52 Week Range | 1.4500 - 4.8500 |
| Volume | |
| Avg. Volume | 11,105 |
| Market Cap | 114.007M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileDefence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously announced proceeds of $5,494,375 on March 17, 2023, it has received additional proceeds in the aggregate amount of $2,308,625 from the exercise of warrant
NewsfileBreakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinical study evaluating the therapeutic potency of a second-generation ARM vaccine targeting solid tumors.The AccumTM technology holds a promising future
- Newsfile
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics is a Canadian biotech company that develops immune-related cancer therapies with proprietary technology. With three clinical trials scheduled by year-end, the company offers growth potential for investors. Defence is seeking to license its technology to enhance other companies' products in the pharmaceutical industry.Cannot view this video? Visit:https://ww
- Newsfile
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2023) - On FOX Business News broadcast on Sunday, May 7 at 5:30 ET - BTV - Business Television interviews emerging companies in the markets with the following companies: Cannot view this video? Visit:https://www.youtube.com/watch?v=1GTcEUiLUzUChampion Iron Limited (OTCQX: CIAFF) (TSX: CIA) (ASX: CIA) - BTV checks in with Champion Iron, a leading producer of high-purity iron ore contributing to decarbonize the steel industry. Its Québec-based
NewsfileDefence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required pre-clinical efficacy studies regarding its AccuTOXTM program. AccuTOXTM is one of Defence's most advanced research and ...
NewsfileUSPTO Grants Trademark Registration for Defence Therapeutics(R)
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®.This trademark is granted under registration number 7,033,299 for products such as "vaccines for human use; me
NewsfileDefence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and Trademark Office (USPTO). The US patent broadly covers Defence's AccumTM-based vacci
NewsfileDefence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therapeutic potency of "naked" to AccumTM-linked mRNA in immunocompetent mice. This first set of studies aims to validate a recently achieved milestone rega
NewsfileRETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to AccumTM. The potency of this modified product will now be compared to "naked" mRNA administered as vaccines in imm
NewsfileDefence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to AccumTM. The potency of this modified product will now be compared to "naked" mRNA administered as vaccines in imm
NewsfileDefence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it is currently conducting a final pre-clinical study aimed at validating the efficacy of AccuTOXTM combined to immune-checkpoint inhibitors akin to the clinical design to be used on p
NewsfileDefence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that over the course of the last 6 months the Company has received over $5 million in gross proceeds from the exercise of warrants, pursuant an early warrant exercise program (the "Early Warrant Exercise Program").To
NewsfileDefence Therapeutics Signs Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), is pleased to announce that it has signed a Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation of radio-immunoconjugates for radio-immunotherapy using Defence's intracellular targeting technology. The no
NewsfileDefence's Pipeline Advances to Multiple Phase I Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to update its stakeholders on its completed achievements as well as outlining the future milestones set for 2023.Over the last three years, Defence has been heavily active in developing its AccumTM
NewsfileDefence Delegates City of Hope to Initiate IND Filing for Its AccuTOX(TM) Cancer Program
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it signed an agreement with City of Hope National Medical Center and Beckman Research Institute of the City of Hope, one of the best and most renowned Cancer Institute Hospital in .
NewsfileRETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing in preparation of its Phase I clinical trial targeting patients with solid cancer tumors. Defence is continuously striving to exploit its AccumT
NewsfileDefence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing in preparation of its Phase I clinical trial targeting patients with solid cancer tumors. Defence is continuously striving to exploit its AccumT
NewsfileDefence Therapeutics and CQDM Fund the Development of a New Cancer Vaccine Platform
Montreal, Quebec--(Newsfile Corp. - February 2, 2023) - In celebration of World Cancer Day, Defence Therapeutics and CQDM are proud to announce the launch of a collaborative research project between Université de Montréal (UdeM), the Lady Davis Institute of the Jewish General Hospital and Defence Therapeutics, a Quebec-based biotechnology company specialized in the development of next-generation vaccines. The funding of this study, totalling $1,359,851, was made possible through a $601,938 grant
NewsfileDefence's Lung Cancer GLP tox Study on Its Intranasal AccuTOX(TM) Formulation Advances
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its GLP studies on a new intranasal AccuTOXTM formulation. This milestone is crucial to initiate a Phase I trial for this drug in the context of lung cancer. ...
NewsfileDefence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%. Defence used a variant of the AccumTM (the A1) to reprogram innate MSCs ...
NewsfileRETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York Ma
NewsfileDefence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023, the Immuno-Oncology 360º "IO360º" premier meeting across all stakeholders in Immuno-Oncology during the 2023 summit at the New-York Ma
NewsfileDefence Accum(TM) Accepted Us Patent to Bolster Its Vaccine Platform Technology IP
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugate ("ADC"), is pleased to announce that that the United States Patent and Trademark Office (USPTO) has issued a Notice of allowance for their US patent application n
NewsfilemRNA with Defence's Accum(TM) Program Has Been Initiated
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program. This R&D program will not only impact the field of cancer immunotherapy, but it can also be directly applied to t
- Baystreet
Stocks in play: Defence Therapeutics Inc.
Just completed a pre-clinical study using its intranasal formulation of AccuTOXTM in the context of ...